Hamm Karsten, Reents Wilko, Zacher Michael, Halbfass Philipp, Kerber Sebastian, Diegeler Anno, Schieffer Bernhard, Barth Sebastian
Department of Cardiology, Cardiovascular Center Bad Neustadt, Bad Neustadt, Germany.
EuroIntervention. 2017 Jun 2;13(2):e161-e167. doi: 10.4244/EIJ-D-17-00011.
We aimed to evaluate the effect of omitting predilation on feasibility, procedural results and safety in balloon-expandable TAVI.
We performed an analysis of all 680 patients scheduled for a balloon-expandable TAVI prosthesis between January 2011 and August 2016. Patients treated with or without predilation were compared. Procedure times decreased from 85.6±42.9 to 56.7±26.1 minutes (p<0.001), fluoroscopy times from 9.5±5.7 to 6.2±3.9 minutes (p<0.001) and contrast volume from 131.9±60.8 to 85.4±37.4 ml (p<0.001) without predilation. Intraprocedural CPR was significantly more frequent in the predilation group (5.3% vs. 1.4%, p=0.01). Stroke rate was low at 1.5% and with no detectable difference. Applying VARC-2 definitions, the combined endpoints device success (88.3% vs. 92.4%, p=0.07) and clinical efficacy (88.7% vs. 92.4%, p=0.11) were comparable with or without prior valvuloplasty, while early safety was less frequent with predilation (85.2% vs. 90.2%, p=0.04). At 30 days, all-cause mortality and cardiovascular mortality were 6.8% with predilation vs. 2.9% without predilation (p=0.03) and 5.3% vs. 1.4% (p=0.01).
TAVI without prior valvuloplasty is feasible without apparent adverse impact in patients receiving a balloon-expandable TAVI prosthesis. The omission of predilation is associated with shorter procedure time, less radiation exposure and lower rates of intraprocedural resuscitation.
我们旨在评估在球囊扩张式经导管主动脉瓣置入术(TAVI)中省略预扩张对可行性、手术结果和安全性的影响。
我们对2011年1月至2016年8月期间计划接受球囊扩张式TAVI假体植入的所有680例患者进行了分析。比较了接受或未接受预扩张治疗的患者。省略预扩张后,手术时间从85.6±42.9分钟降至56.7±26.1分钟(p<0.001),透视时间从9.5±5.7分钟降至6.2±3.9分钟(p<0.001),造影剂用量从131.9±60.8毫升降至85.4±37.4毫升(p<0.001)。预扩张组术中心肺复苏(CPR)的频率明显更高(5.3%对1.4%,p=0.01)。卒中发生率较低,为1.5%,且无明显差异。应用瓣膜学术研究联合会(VARC)-2定义,无论是否进行过瓣膜成形术,器械成功(88.3%对92.4%,p=0.07)和临床疗效(88.7%对92.4%,p=0.11)的复合终点相当,而预扩张时早期安全性事件的发生率较低(85.2%对90.2%,p=0.04)。在30天时,预扩张组的全因死亡率和心血管死亡率分别为6.8%和5.3%,未预扩张组分别为2.9%和1.4%(p=0.03和p=0.01)。
对于接受球囊扩张式TAVI假体植入的患者,不进行瓣膜成形术的TAVI是可行的,且无明显不良影响。省略预扩张与更短的手术时间、更少的辐射暴露以及更低的术中复苏率相关。